This report provides a summary and key points of presentations and discussions made during an IPC symposium presented by IPC's Research Committee held during the Society of Investigative Dermatology (SID) Annual Meeting in Chicago, IL, USA
download
SYMPOSIUM REPORT - Challenging Cases: A focus on pediatrics, comorbidities, infections, & biologics
This report provides a summary and key points of presentations and challenging case discussions made during an IPC symposium held during the Skin Inflammation and Psoriasis International Network (SPIN) Congress in Paris, France
psoriasis and atopic dermatitis: similarities and differences
A joint publication of the International Eczema Council (IEC) and the International Psoriasis Council (IPC)
2018 IPC Think tank meeting report
This report provides a meeting summary and key points of presentations and discussions held during IPC's 2018 Think Tank
GLOBAL PSORIASIS ATLAS ANNUAL REPORT 2019
The annual report highlights the outcomes for Year 2: April 2018-March 2019
p4 medicine: Personalized, predictive, preventive, participatory medicine in a digital environment - HOW CAN THE INTERNATIONAL PSORIASIS COUNCIL CONTRIBUTE?
An IPC written article discussing the importance of the P4 approach to medicine
Global Psoriasis Atlas Annual Report 2018
The annual report highlights the outcomes for Year 1: April 2017-March 2018
The IPC contributed to the the WHO Global Report on Psoriasis (2016) and subsequently launched the Global Psoriasis Atlas project in April 2017
UPCOMING EVENT The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory? Wednesday, September 18, 2019 2:00 pm - 6:00 pm Bordeaux, france Register Now
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News